Nurses prepare patients’ treatments in the pharmacy of the ambulatory ward at the National Centre for Tuberculosis and Lung Disease in Georgia’s capital, Tbilisi. (Daro Sulakauri/MSF)

Nurses prepare patients’ treatments in the pharmacy of the ambulatory ward at the National Centre for Tuberculosis and Lung Disease in Georgia’s capital, Tbilisi. (Daro Sulakauri/MSF)

The latest on the endTB trials results and the Unitaid call for proposals

The endTB results will be presented in November 2023, at the Union World Conference. Read more about the confernece presentations here.

The endTB trial results will inform the development of project proposals to be submitted to Unitaid’s recently released call for proposals. We welcome any request for information or support from applicants after the results presentation in mid-November; please contact us via: [email protected]

endTB-Q results will be made public in early 2025. Proposals could already anticipate additional work packages to support introduction depending on the results.

      Testing novel, short, all-oral regimens for MDR-TB

Médecins Sans Frontières (MSF), Partners In Health (PIH), Interactive Research and Development (IRD), and their partners have launched two major clinical trials which seek to revolutionize treatment for the toughest strains of tuberculosis (TB), the world’s leading infectious disease killer.

The two clinical trials are sponsored by MSF. The Principal Investigators are Carole Mitnick (Harvard Medical School) and Lorenzo Guglielmetti (MSF).

Epicentre, Harvard Medical School, the Institute of Tropical Medicine Antwerp and UCSF are partners of the trials.

       Why these clinical trials?

Conventional treatments for MDR-TB are long (up to 24 months), ineffective (only 59% treatment success in 2018) and often cause terrible side effects, including acute psychosis and permanent deafness. All the while, patients ingest up to 14,000 pills and some of them have to endure months of painful, daily injections. Moreover, the costliness, difficulty and length of current treatments make them hard to implement in many high-burden countries.

To address the problem, the two clinical trials use the first TB drugs developed in almost 50 years — bedaquiline and delamanid — to find radically shorter (6 or 9 months), more tolerable, injection-free treatments for MDR-TB.  

1. endTB trial (fluoroquinolone-susceptible MDR-TB)

The endTB clinical trial was expected to enroll 750 patients across eight countries: Georgia, India, KazakhstanLesotho, PakistanPeru and South Africa. These are all countries with significant TB burdens, where MSF, PIH or IRD support local MDR-TB treatment activities.

In October 2021, enrolment was completed with the overall inclusion of 754 patients.

       Study design

endTB is a randomized, controlled, Phase III clinical trial testing five new, all oral, 9-month regimens compared to the current standard of care. Randomization was outcome-adapted, rather than fixed. This means that the probability of being randomized to regimens changed as the outcomes were reported: more patients were assigned to regimens that were producing better outcomes. A summary of the study protocol has been published and is publicly available here.

       Study treatment regimens

Each experimental regimen contains at least one new drug, in combination with up to four companion drugs. The control regimen is the local standard of care consistent with latest WHO recommendations, including bedaquiline and/or delamanid if indicated.

endTB table

2. endTB-Q trial (fluoroquinolone-resistant MDR-TB)

The endTB-Q clinical trial is expected to enroll 324 patients across six countries (India, Kazakhstan, Lesotho, PakistanPeru, and Vietnam) to find simpler, less toxic, shorter regimen for fluoroquinolone-resistant MDR-TB. 

In March 2023, enrolment was completed with an overall inclusion of 324 patients.

       Study design

This is a randomized, controlled, Phase III clinical trial testing a new, all oral regimen compared to the current standard of care.

       Study treatment regimen

The experimental regimen contains bedaquiline, delamanid, clofazimine, and linezolid, and is delivered for 24 or 39 weeks. endTB-Q adopts a personalized medicine approach, by individualizing the treatment duration based on baseline characteristics and treatment response of each participant.

The control arm regimen designed and delivered according to local standard of care and consistent with latest WHO guidelines and may include bedaquiline and/or delamanid in addition to other drugs.

Q table

       Study oversight

Several independent groups provide formal external oversight of the study protocols, implementation, operation and analysis:

  • Institutional Review Boards or Ethics Committees at MSF, Harvard Medical School, IRD, Antwerp Institute of Tropical Medicine, and in each country participating in the clinical trial
  • Independent Scientific Advisory Committee (SAC)
  • Global Community Advisory Board, convened by the Treatment Action Group
  • Data Safety and Monitoring Board (DSMB)

These groups will continue to assure the relevance of the trials for clinical care and policy, their safety for participants, and that global standards for clinical research are met or exceeded.  

       Technical resources

PIH MSF MSF Unitaid: Save Lives Faster Médecins Sans Frontières (MSF) Transformational Investment Capacity (TIC) logo